# US 2025/0319201 A1 · Mutant of adeno-associated virus and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0319201 A1
- Document ID: US20250319201A1
- Status: Published application
- Kind: A1
- Application number: 19/253,966
- Filed: 2025-07-10
- Published: 2025-10-16
- Earliest claimed: 2022-12-30
- Assignees: Packgene Biotech Co., Ltd.
- Applicants: Packgene Biotech Co., Ltd.
- Inventors: Huapeng Li; Ye Bu; Yujian Zhong; Zhiyong Dai; Youwei Zhang; Yue Pan; Huan Chen
- Web page: https://patentgrep.com/patent/US20250319201A1

## CPC

- A61K 48/0041: {the non-active part being polymeric}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07K 14/005: from viruses
- C07K 14/015: Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/86: Viral vectors
- C12N 15/864: Parvoviral vectors {, e.g. parvovirus, densovirus}
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14151: Methods of production or purification of viral material
- C12R 2001/91: Cell lines {; Processes using cell lines}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The present disclosure provides a mutant of an adeno-associated virus 2 (AAV2) capsid protein, including an amino acid sequence KTINGSGQNQQTLK (SEQ ID NO: 2) or an amino acid sequence having 1, 2, 3, or 4 amino acid changes when compared to SEQ ID NO: 2 in variable region IV; and an amino acid sequence TTVTQ (SEQ ID NO: 3) or an amino acid sequence having 1 or 2 amino acid changes when compared to SEQ ID NO: 3 in variable region V. The mutants of an adeno-associated virus provided herein have low liver tropism and low hepatotoxicity.

## Claims

### Claim 1

A mutant of an adeno-associated virus 2 (AAV2) capsid protein, comprising:
an amino acid sequence KTINGSGQNQQTLK (SEQ ID NO: 2) or an amino acid sequence having 1, 2, 3, or 4 amino acid changes when compared to SEQ ID NO: 2 in variable region IV; and
an amino acid sequence TTVTQ (SEQ ID NO: 3) or an amino acid sequence having 1 or 2 amino acid changes when compared to SEQ ID NO: 3 in variable region V.

### Claim 2 (depends on 1)

The mutant of the AAV2 capsid protein according to claim 1, wherein 12-16 consecutive amino acids in the variable region IV of a wild-type AAV2 capsid protein are replaced by the amino acid sequence KTINGSGQNQQTLK (SEQ ID NO: 2) or the amino acid sequence having 1, 2, 3, or 4 amino acid changes when compared to SEQ ID NO: 2, and
wherein 4-6 consecutive amino acids in the variable region V of the wild-type AAV2 capsid protein are replaced by the amino acid sequence TTVTQ (SEQ ID NO: 3) or an amino acid sequence having 1 or 2 amino acid changes when compared to SEQ ID NO: 3.

### Claim 3 (depends on 1)

The mutant of the AAV2 capsid protein according to claim 1, wherein amino acids at positions 447-461 of a wild-type AAV2 capsid protein are replaced by the amino acid sequence KTINGSGQNQQTLK (SEQ ID NO: 2) or the amino acid sequence having 1, 2, 3, or 4 amino acid changes when compared to SEQ ID NO: 2,
wherein amino acids at positions 490-494 of the wild-type AAV2 capsid protein are replaced by the amino acid sequence TTVTQ (SEQ ID NO: 3) or the amino acid sequence having 1 or 2 amino acid changes when compared to SEQ ID NO: 3, and
wherein the positions of the amino acids correspond to positions in an amino acid sequence of the wild-type VP1 protein set forth in SEQ ID NO: 1.

### Claim 4 (depends on 2)

The mutant of the AAV2 capsid protein according to claim 2, wherein amino acids at positions 447-461 of the wild-type AAV2 capsid protein are replaced by the amino acid sequence KTINGSGQNQQTLK (SEQ ID NO: 2) or the amino acid sequence having 1, 2, 3, or 4 amino acid changes when compared to SEQ ID NO: 2,
wherein amino acids at positions 490-494 of the wild-type AAV2 capsid protein are replaced by the amino acid sequence TTVTQ (SEQ ID NO: 3) or the amino acid sequence having 1 or 2 amino acid changes when compared to SEQ ID NO: 3, and
wherein the positions of the amino acids correspond to positions in an amino acid sequence of the wild-type VP1 protein set forth in SEQ ID NO: 1.

### Claim 5 (depends on 1)

The mutant of the AAV2 capsid protein according to claim 1, wherein an amino acid sequence RTNTPSGTTTQSRLQ (SEQ ID NO: 4) in the variable region IV of a wild-type AAV2 capsid protein is replaced by the amino acid sequence KTINGSGQNQQTLK (SEQ ID NO: 2) or the amino acid sequence having 1, 2, 3, or 4 amino acid changes when compared to SEQ ID NO: 2, and
wherein an amino acid sequence KTSAD (SEQ ID NO: 5) in the variable region V of the wild-type AAV2 capsid protein is replaced by the amino acid sequence TTVTQ (SEQ ID NO: 3) or the amino acid sequence having 1 or 2 amino acid changes when compared to SEQ ID NO: 3.

### Claim 6 (depends on 1)

The mutant of the AAV2 capsid protein according to claim 1, wherein the amino acid at position 585 is a non-basic amino acid, and wherein the position of the amino acid corresponds to a position in an amino acid sequence of the wild-type VP1 protein set forth in SEQ ID NO: 1.

### Claim 7 (depends on 1)

The mutant of the AAV2 capsid protein according to claim 1, wherein arginine (R) at position 585 of a wild-type AAV2 capsid protein is mutated to alanine (A), and wherein the position of the arginine or alanine corresponds to a position in an amino acid sequence of the wild-type VP1 protein set forth in SEQ ID NO: 1.

### Claim 8 (depends on 1)

The mutant of the AAV2 capsid protein according to claim 1, wherein amino acids at positions 585-587 of a wild-type AAV2 capsid protein are deleted, and wherein the positions of the amino acids correspond to positions in an amino acid sequence of the wild-type VP1 protein set forth in SEQ ID NO: 1.

### Claim 9 (depends on 1)

The mutant of the AAV2 capsid protein according to claim 1, which is a mutant of capsid protein VP1, VP2 and/or VP3.

### Claim 10 (depends on 1)

The mutant of the AAV2 capsid protein according to claim 1, comprising an amino acid sequence set forth in any one of SEQ ID NOs: 6-8, or an amino acid sequence having at least 80%, at least 90%, at least 95%, or at least 98% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOs: 6-8.

### Claim 11 (depends on 1)

An isolated nucleic acid molecule encoding the mutant of the AAV2 capsid protein according to claim 1.

### Claim 12 (depends on 11)

The isolated nucleic acid molecule according to claim 11, comprising a nucleotide sequence set forth in any one of SEQ ID NOs: 10-12.

### Claim 13 (depends on 11)

An expression vector comprising the isolated nucleic acid molecule according to claim 11.

### Claim 14 (depends on 12)

An expression vector comprising the isolated nucleic acid molecule according to claim 12.

### Claim 15 (depends on 11)

A host cell comprising the isolated nucleic acid molecule according to claim 11.

### Claim 16 (depends on 13)

A host cell comprising the expression vector according to claim 13.

### Claim 17 (depends on 1)

A host cell, which expresses the mutant of the AAV2 capsid protein according to claim 1.

### Claim 18 (depends on 1)

An adeno-associated virus (AAV) comprising the mutant of the AAV2 capsid protein according to claim 1.

### Claim 19 (depends on 11)

A method for preparing a recombinant adeno-associated virus (rAAV), comprising:
introducing at least the following components into a host cell:
(1) the isolated nucleic acid molecule according to claim 11 or an expression vector comprising the isolated nucleic acid molecule according to claim 11; and
(2) a GOI (gene of interest) plasmid comprising a target gene.

### Claim 20 (depends on 19)

The method according to claim 19, wherein an expression product of the target gene is protein or RNA.

### Claim 21 (depends on 19)

A rAAV prepared by the method according to claim 19.

### Claim 22 (depends on 21)

The rAAV according to claim 21, which has lower targeting to liver than a wild-type AAV2 or wild-type AAV9.

### Claim 23 (depends on 21)

The rAAV according to claim 21, which has higher targeting to muscle, heart, brain, spinal cord, lung, kidney, or eye than a wild-type AAV2 or wild-type AAV9.

### Claim 24 (depends on 21)

A pharmaceutical composition comprising the rAAV according to claim 21 and a pharmaceutically acceptable carrier.

### Claim 25 (depends on 11)

A pharmaceutical composition comprising the isolated nucleic acid molecule according to claim 11 or an expression vector comprising the isolated nucleic acid molecule according to claim 11 and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 25)

A method for treating a muscle, heart, brain, spinal cord, lung, kidney, or eye-related disease, comprising:
administering a therapeutically effective amount of the pharmaceutical composition according to claim 25 to a patient suffering from the muscle, heart, brain, spinal cord, lung, kidney, or eye-related disease, wherein the pharmaceutical composition comprises a heterologous polynucleotide encoding a heterologous gene product.

### Claim 27 (depends on 24)

A method for treating a muscle, heart, brain, spinal cord, lung, kidney, or eye-related disease, comprising:
administering a therapeutically effective amount of the pharmaceutical composition according to claim 24 to a patient suffering from the muscle, heart, brain, spinal cord, lung, kidney, or eye-related disease, wherein the pharmaceutical composition comprises a heterologous polynucleotide encoding a heterologous gene product.
